Case Study: Glytec achieves rapid publication of critical COVID-19 glycemic research with Sisense

Glytec Rapidly Analyzes Data to Publish Critical Medical Research During COVID-19

Glytec delivers FDA-cleared, patient-centric insulin-management software to improve outcomes and reduce costs for the 34 million Americans with diabetes and the 30–40% of hospitalized patients who require insulin. During COVID-19, legacy one-size-fits-all insulin practices and pressures to limit patient contact (PPE shortages, reduced monitoring) threatened care, so Glytec needed to rapidly educate clinicians and prove that personalized glycemic management could prevent harm.

Using Sisense to analyze data from 88 hospitals, Glytec quickly visualized trends, published the study "Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States," and showed dramatically higher mortality—7X for patients who developed glycemic issues in-hospital and 4X for patients with preexisting glycemic problems. Time-to-insight fell from days to minutes, enabling real-time tracking of tens of thousands of patients, faster publication of life‑saving recommendations, and clearer evidence for more frequent, targeted glucose monitoring and insulin management.

Glytec

Robby Booth

Founder and SVP